Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 40 results for prostatic hyperplasia

  1. Adoption of UroLift procedure, an ambulatory pathway for patients suffering from Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia

    2016 Benign Prostate Hyperplasia (BPH) is a long-term and progressive condition, resulting in lower urinary

    Shared learning
    Last updated
    12 September 2019

  2. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic...

    Research recommendation
    Published
    30 September 2022

  3. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  4. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic...

    Research recommendation
    Published
    18 February 2019

  5. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  6. Urolift – a community-based alternative treatment for Benign Prostatic Obstruction (BPO)

    introduced Urolift, a minimally invasive day case treatment for Benign Prostatic Obstruction (BPO), which enabled us to move the service...

    Shared learning
    Last updated
    10 March 2020

  7. Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.

    Awaiting development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  8. Northampton General Day Case BPH service evaluation – adoption of Urolift

    patients as alternative to TURP for troublesome symptoms of Benign Prostate Hyperplasia (BPH) would result in cost and efficiency...

    Shared learning
    Published
    17 January 2020

  9. NICE encourages further research and publication of results from consecutive case series of patients having this procedure. Details of patient selection should be clearly documented. Reported outcomes should include the effects of the procedure on symptoms and quality of life, the duration of benefits, and the need for further procedures. All complications should be reported. NICE may review this procedure in the light of longer-term outcomes.

    safety of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic...

    Research recommendation
    Published
    9 June 2015

  10. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

    Clinical guideline
    Last updated
    3 June 2015
    View recommendations

    Sections for CG97

  11. Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.

    UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Number MTG58 Date issued May 2021 Other

    Research recommendation
    Published
    10 August 2021

  12. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

    Medtech innovation briefing
    Published
    2 October 2017

  13. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    31 October 2018
    View recommendations

    Sections for NG112

  14. Rezum for treating benign prostatic hyperplasia (MIB158)

    This advice has been updated and replaced by NICE medical technologies guidance 49. 

    Medtech innovation briefing
    Published
    24 August 2018

  15. Prostate artery embolisation for benign prostatic hyperplasia (IPG453)

    This guidance has been updated and replaced by NICE interventional procedures guidance 611.

    Interventional procedures guidance
    Published
    26 April 2013